Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
11.59
+0.24 (2.11%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Immatics Employees
As of December 31, 2025, Immatics had 711 total employees, including 589 full-time and 122 part-time employees. The number of employees increased by 29 or 4.25% compared to the previous year.
Employees
711
Change (1Y)
29
Growth (1Y)
4.25%
Revenue / Employee
$79,705
Profits / Employee
-$324,406
Market Cap
1.55B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 298 |
| Monte Rosa Therapeutics | 150 |
| Nanobiotix | 103 |
| AtaiBeckley | 99 |
| Rapport Therapeutics | 84 |
IMTX News
- 7 days ago - Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting - GlobeNewsWire
- 4 months ago - Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewsWire
- 5 months ago - Immatics Announces $125 Million Underwritten Offering - GlobeNewsWire
- 5 months ago - Immatics Transcript: Study Update - Transcripts
- 5 months ago - Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewsWire
- 6 months ago - Immatics Appoints Amie Krause as Chief People Officer - GlobeNewsWire
- 6 months ago - Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium - GlobeNewsWire
- 9 months ago - Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire